argen X VYVGART and VYVGART Hytrulo Drive Transformative Outcomes in Debilitating Autoimmune Disease

 

• ADHERE data show VYVGART®Hytrulo has potential to be first advancement for CIDP patients in 30 years
• Real-world data demonstrate gMG patients able to significantly reduce steroid use over first six months of initiating VYVGART® treatment

https://www.biospace.com/article/releases/argenx-data-highlight-evidence-that-vyvgart-and-vyvgart-hytrulo-drive-transformative-outcomes-for-patients-with-debilitating-autoimmune-disease-/